During the treatment of Valemetostat, hematological toxicity and drug interactions are key issues that affect efficacy and safety, and require focused monitoring and prevention.

1、 Monitoring and treatment of thrombocytopenia

1. Risk awareness

Vametostat can cause thrombocytopenia and increase the risk of bleeding. Regular blood routine check and close monitoring of platelet count should be conducted before and during treatment.

2. Observation of bleeding symptoms

Pay attention to skin bruising, ecchymoses, gum bleeding, nosebleeds, black stools, or hematuria. Once abnormal bleeding occurs, the doctor should be informed immediately.

3. Daily protection

During the period of thrombocytopenia, avoid bumping, vigorous exercise, and the use of sharp objects. It is recommended to use a soft bristled toothbrush for brushing teeth and an electric shaver for shaving.

4. Avoid co administration of drugs that affect platelets

Non steroidal anti-inflammatory drugs, aspirin, anticoagulants, etc. may increase the risk of bleeding, and should be consulted with a doctor before use.

5. Dose adjustment

If there is a severe decrease in platelets, doctors may suspend medication, reduce dosage, or permanently stop medication, and patients cannot adjust on their own.

2、 Monitoring and Management of Anemia

1. Risk awareness

Vametostat can cause anemia, manifested as fatigue, dizziness, shortness of breath, pale complexion, etc. Hemoglobin should be monitored regularly during treatment.

2. Symptom observation

If palpitations, obvious fatigue, or difficulty breathing occur after activity, seek medical attention promptly to assess the degree of anemia.

3. Nutritional support

Moderate intake of foods rich in iron, folate, and vitamin B12, such as lean meat, animal liver, green leafy vegetables, and legumes, can help improve anemia.

4. Blood transfusion if necessary

Severe anemia patients may require blood transfusion treatment, which should be determined by a doctor based on hemoglobin levels and clinical symptoms.

5. Dose adjustment

When anemia is severe, doctors may suspend medication or reduce the dosage, and it is necessary to follow the doctor's advice.

3、 Drug interactions

1. CYP3A related interactions

Valmet is mainly metabolized by CYP3A. Strong CYP3A inhibitors (such as ketoconazole and clarithromycin) may increase their blood drug concentration and toxicity; Strong inducers such as rifampicin and carbamazepine may reduce efficacy.

2. Grapefruit taboos

During medication, grapefruit and its juice should be avoided to avoid affecting drug metabolism.

3. Anticoagulants and antiplatelet drugs

When used in combination with anticoagulants and antiplatelet drugs, the risk of bleeding increases, and caution should be exercised after evaluation by a doctor.

4. Other bone marrow suppressive drugs

The combination with chemotherapy drugs, radiotherapy, or other bone marrow suppressive drugs may exacerbate hematological toxicity, and blood routine should be closely monitored.

5. Notify medication history

When seeking medical attention, it is important to proactively inform the doctor of all prescription drugs, over-the-counter drugs, and health supplements being used to avoid potential interactions.